Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents.

Article Details

Citation

Copy to clipboard

Miyagi M, Arai N, Taya F, Itoh F, Komatsu Y, Kojima M, Isaji M

Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents.

Biol Pharm Bull. 1996 Nov;19(11):1499-502.

PubMed ID

8951172 [ View in PubMed

]

Abstract

We studied the characterization of cabergoline, a new ergot alkaloid derivative and a selective dopamine D2 receptor agonist, in comparison to bromocriptine and pergolide in reserpine-treated rodents. Cabergoline (0.25-1.0 mg/kg, s.c.) improved dose-dependently the reserpine-induced akinesia that was assessed on the locomotor activity, and the efficacy lasted longer than those of bromocriptine (1.25-5.0 mg/kg, s.c.) or pergolide (0.0625-0.5 mg/kg s.c.). Cabergoline (ED50 = 1.10 mg/kg, at 4 h after the administration of drugs) also reversed catalepsy, the failure to correct an externally imposed posture, and its efficacy was stronger and longer than bromocriptine (ED50 = 4.65 mg/kg, at 4 h). Further, reserpine-induced rigidity was improved equally by cabergoline (0.125-1.0 mg/kg, i.v) and bromocriptine (1.0 mg/kg, i.v.). When cabergoline was administered together with 3(3,4-dihydroxyphenyl)-L-alanine (L-DOPA), the effects were additive. Our results indicate that the long-lasting effects of cabergoline could be beneficial for treating Parkinson's disease.

DrugBank Data that Cites this Article

Drugs

Cabergoline

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Cabergoline	Dopamine D2 receptor	Protein	Humans	Yes	Agonist	Details